Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis

References

• ParisiRSymmonsDPGriffithsCEAshcroftDMIdentification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project teamGlobal epidemiology of psoriasis: a systematic review of incidence and prevalenceJ Invest Dermatol2013133237738510.1038/jid.2012.33923014338
   PubMed Web of Science ®Google Scholar
• RachakondaTDSchuppCWArmstrongAWPsoriasis prevalence among adults in the United StatesJ Am Acad Dermatol201470351251610.1016/j.jaad.2013.11.01324388724
   PubMed Web of Science ®Google Scholar
• GuptaMASchorkNJGuptaAKKirkbySEllisCNSuicidal ideation in psoriasisInt J Dermatol19933231881908444530
   PubMed Web of Science ®Google Scholar
• KurdSKTroxelABCrits-ChristophPGelfandJMThe risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort studyArch Dermatol2010146889189510.1001/archdermatol.2010.18620713823
   PubMed Web of Science ®Google Scholar
• DowlatshahiEAWakkeeMArendsLRNijstenTThe prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysisJ Invest Dermatol201413461542155110.1038/jid.2013.50824284419
   PubMed Web of Science ®Google Scholar
• RappSRFeldmanSRExumMLFleischerABJrReboussinDMPsoriasis causes as much disability as other major medical diseasesJ Am Acad Dermatol1999413 Pt 140140710459113
   PubMed Web of Science ®Google Scholar
• VillaniAPRouzaudMSevrainMPrevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysisJ Am Acad Dermatol201573224224810.1016/j.jaad.2015.05.00126054432
   PubMed Web of Science ®Google Scholar
• YeungHTakeshitaJMehtaNNPsoriasis severity and the prevalence of major medical comorbidity: a population-based studyJAMA Dermatol2013149101173117910.1001/jamadermatol.2013.501523925466
   PubMed Web of Science ®Google Scholar
• LanganSMSeminaraNMShinDBPrevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United KingdomJ Invest Dermatol20121323 Pt 155656210.1038/jid.2011.36522113483
   PubMed Web of Science ®Google Scholar
• MehtaNNAzfarRSShinDBNeimannALTroxelABGelfandJMPatients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research DatabaseEur Heart J20103181000100610.1093/eurheartj/ehp56720037179
   PubMed Web of Science ®Google Scholar
• GelfandJMNeimannALShinDBWangXMargolisDJTroxelABRisk of myocardial infarction in patients with psoriasisJAMA2006296141735174110.1001/jama.296.14.173517032986
   PubMed Web of Science ®Google Scholar
• GelfandJMTroxelABLewisJDThe risk of mortality in patients with psoriasis: results from a population-based studyArch Dermatol2007143121493149910.1001/archderm.143.12.149318086997
   PubMed Web of Science ®Google Scholar
• JoshiAALermanJBDeyAKAssociation between aortic vascular inflammation and coronary artery plaque characteristics in psoriasisJAMA Cardiol201831094995610.1001/jamacardio.2018.276930208407
   PubMed Web of Science ®Google Scholar
• MehtaNNYuYSabouryBSystemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot studyArch Dermatol201114791031103910.1001/archdermatol.2011.11921576552
   PubMedGoogle Scholar
• MehtaNNTorigianDAGelfandJMSabouryBAlaviAQuantification of atherosclerotic plaque activity and vascular inflammation using [18-F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT)J Vis Exp201263e3777
   PubMed Web of Science ®Google Scholar
• BhutaniTPatelTKooBNguyenTHongJKooJA prospective, interventional assessment of psoriasis quality of life using a nonskin-specific validated instrument that allows comparison with other major medical conditionsJ Am Acad Dermatol2013692e79e8810.1016/j.jaad.2012.10.00923207011
   PubMed Web of Science ®Google Scholar
• GelfandJMDoes biologic treatment of psoriasis lower the risk of cardiovascular events and mortality?: a critical question that we are only just beginning to answerJ Am Acad Dermatol2018791697010.1016/j.jaad.2018.03.04629625133
   PubMed Web of Science ®Google Scholar
• WuJJSundaramMCloutierMThe risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus phototherapy: an observational cohort studyJ Am Acad Dermatol2018791606829499292
   PubMed Web of Science ®Google Scholar
• MehtaNNShinDBJoshiAAEffect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: a randomized placebo-controlled trialCirc Cardiovasc Imaging2018116e00739410.1161/CIRCIMAGING.117.00739429776990
   PubMed Web of Science ®Google Scholar
• PappKABlauveltABukhaloMRisankizumab versus ustekinumab for moderate-to-severe plaque psoriasisN Engl J Med2017376161551156010.1056/NEJMoa160701728423301
   PubMed Web of Science ®Google Scholar
• BosJDHulseboschHJKriegSRBakkerPMCormaneRHImmunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodiesArch Dermatol Res198327531811896604503
   PubMed Web of Science ®Google Scholar
• AricanOAralMSasmazSCiragilPSerum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severityMediators Inflamm20052005527327910.1155/MI.2005.27316258194
   PubMed Web of Science ®Google Scholar
• IwakuraYIshigameHThe IL-23/IL-17 axis in inflammationJ Clin Invest200611651218122210.1172/JCI2850816670765
   PubMed Web of Science ®Google Scholar
• NestleFOKaplanDHBarkerJPsoriasisN Engl J Med2009361549650910.1056/NEJMra080459519641206
   PubMed Web of Science ®Google Scholar
• OppmannBLesleyRBlomBNovel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12Immunity200013571572511114383
   PubMed Web of Science ®Google Scholar
• McIntyreKWShusterDJGilloolyKMReduced incidence and severity of collagen-induced arthritis in interleukin-12-deficient miceEur J Immunol199626122933293810.1002/eji.18302612198977288
   PubMed Web of Science ®Google Scholar
• NeurathMFFussIKelsallBLStuberEStroberWAntibodies to interleukin 12 abrogate established experimental colitis in miceJ Exp Med19951825128112907595199
   PubMed Web of Science ®Google Scholar
• ChuCQWittmerSDaltonDKFailure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitisJ Exp Med2000192112312810880533
   PubMed Web of Science ®Google Scholar
• FerberIABrockeSTaylor-EdwardsCMice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE)J Immunol19961561578598493
   PubMed Web of Science ®Google Scholar
• VermeireKHeremansHVandeputteMHuangSBilliauAMatthysPAccelerated collagen-induced arthritis in IFN-gamma receptor-deficient miceJ Immunol199715811550755139164974
   PubMed Web of Science ®Google Scholar
• BettelliESullivanBSzaboSJSobelRAGlimcherLHKuchrooVKLoss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitisJ Exp Med20042001798710.1084/jem.2003181915238607
   PubMed Web of Science ®Google Scholar
• WangXWeiYXiaoHA novel IL-23p19/Ebi3 (IL-39) cytokine mediates inflammation in Lupus-like miceEur J Immunol20164661343135010.1002/eji.20154609527019190
   PubMed Web of Science ®Google Scholar
• TREMFYA (guselkumab) [package insert]Horsham (PA)Janssen Biotech Inc2017
   Google Scholar
• AhnCSDothardEHGarnerMLFeldmanSRHuangWWTo test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritisJ Am Acad Dermatol2015733420428.e110.1016/j.jaad.2015.06.00426184440
   PubMed Web of Science ®Google Scholar
• HoffmannJHKnoopCEnkAHHadaschikENRoutine laboratory parameter dynamics and laboratory adverse events in psoriasis patients on long-term treatment with adalimumab, etanercept, and ustekinumabActa Derm Venereol201797670571010.2340/00015555-264428224166
   PubMed Web of Science ®Google Scholar
• HalverstamCPLebwohlMPractical management and monitoring of psoriasis in patients on biologic therapyPsoriasis Forum2007132
   Google Scholar
• NastAGisondiPOrmerodADEuropean S3-guidelines on the systemic treatment of psoriasis vulgaris–update 2015–short version–EDF in cooperation with EADV and IPCJ Eur Acad Dermatol Venereol201529122277229410.1111/jdv.1335426481193
   PubMed Web of Science ®Google Scholar
• LebwohlMBagelJGelfandJMFrom the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasisJ Am Acad Dermatol20085819410510.1016/j.jaad.2007.08.03017980456
   PubMed Web of Science ®Google Scholar
• BlauveltAPappKAGriffithsCEEfficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trialJ Am Acad Dermatol201776340541710.1016/j.jaad.2016.11.04128057360
   PubMed Web of Science ®Google Scholar
• ReichKArmstrongAWFoleyPEfficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trialJ Am Acad Dermatol201776341843110.1016/j.jaad.2016.11.04228057361
   PubMed Web of Science ®Google Scholar
• LangleyRGTsaiTFFlavinSEfficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trialBr J Dermatol2017178111412328635018
   PubMed Web of Science ®Google Scholar
• GriffithsCEMPappKAKimballABLong-term efficacy of guselkumab for the treatment of moderate-to-severe psoriasis: results from the Phase 3 VOYAGE 1 trial through two yearsJ Drugs Dermatol201817882683230124721
   PubMed Web of Science ®Google Scholar
• FoleyPGordonKGriffithsCEMEfficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions: a secondary analysis of 2 randomized clinical trialsJAMA Dermatol2018154667668310.1001/jamadermatol.2018.079329799960
   PubMed Web of Science ®Google Scholar
• TeruiTKobayashiSOkuboYMurakamiMHiroseKKuboHEfficacy and safety of guselkumab, an anti-interleukin 23 monoclonal antibody, for palmoplantar pustulosis: a randomized clinical trialJAMA Dermatol2018154330931610.1001/jamadermatol.2017.593729417135
   PubMed Web of Science ®Google Scholar
• van de KerkhofPCReichKKavanaughAPhysician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis surveyJ Eur Acad Dermatol Venereol201529102002201010.1111/jdv.1315025885420
   PubMed Web of Science ®Google Scholar
• MenterAThaciDWuJJLong-term safety and effectiveness of adalimumab for moderate to severe psoriasis: results from 7-year interim analysis of the ESPRIT registryDermatol Ther (Heidelb)20177336538110.1007/s13555-017-0198-x28815476
   PubMed Web of Science ®Google Scholar
• StroberBCrowleyJLangleyRGSystematic review of the real-world evidence of adalimumab safety in psoriasis registriesJ Eur Acad Dermatol Venereol2018322126213310.1111/jdv.2018.32.issue-1230067882
   PubMed Web of Science ®Google Scholar
• STELARA (ustekinumab) [package insert]Horsham (PA)Janssen Biotech Inc2016
   Google Scholar
• SILIQ (brodalumab) [package insert]Bridgewater (NJ)Valeant Pharmaceuticals2017
   Google Scholar
• LebwohlMStroberBMenterAPhase 3 studies comparing brodalumab with ustekinumab in psoriasisN Engl J Med2015373141318132810.1056/NEJMoa150382426422722
   PubMed Web of Science ®Google Scholar
• GordonKBBlauveltAPappKAUNCOVER-1 Study GroupUNCOVER-2 Study GroupUNCOVER-3 Study GroupPhase 3 trials of ixekizumab in moderate-to-severe plaque psoriasisN Engl J Med2016375434535610.1056/NEJMoa151271127299809
   PubMed Web of Science ®Google Scholar
• ContiHRGaffenSLIL-17-mediated immunity to the opportunistic fungal pathogen candida albicansJ Immunol2015195378078810.4049/jimmunol.150090926188072
   PubMed Web of Science ®Google Scholar
• LebwohlMGPappKAMarangellLBPsychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trialsJ Am Acad Dermatol20187818189.e8510.1016/j.jaad.2017.08.02428985956
   PubMed Web of Science ®Google Scholar
• MrowietzUKragballeKReichKDefinition of treatment goals for moderate to severe psoriasis: a European consensusArch Dermatol Res2011303111010.1007/s00403-010-1080-120857129
   PubMed Web of Science ®Google Scholar
• YangEJSanchezIMBeckKSekhonSWuJJBhutaniTGuselkumab for the treatment of moderate-to-severe plaque psoriasisExpert Rev Clin Pharmacol201811433334410.1080/17512433.2018.144596729478344
   PubMed Web of Science ®Google Scholar